Neoadjuvant chemotherapy with FOLFOX4 regimen to treat advanced gastric cancer improves survival without increasing adverse events: a retrospective cohort study from a Chinese center.
Zhen SunRui-Juan ZhuGui-Fang YangYan LiPublished in: TheScientificWorldJournal (2014)
The FOLFOX4 neoadjuvant chemotherapy could improve survival without increasing adverse events in patients with AGC.